Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda US Subsidiary Millennium Begins International PIII Trial on Alisertib
March 7, 2012
- Long-Listed Drugs Account for Over 60% of Eisai’s Sales: Jiho Survey
March 7, 2012
- Worldwide Sales by Biopharmaceutical Contract Manufacturers Down Slightly in 2010 at US$3.4 Billion: Seed Planning
March 7, 2012
- Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
- Eisai President Naito Approves of Government Measures, Saying Japan’s Positioning “Improving Greatly”
March 2, 2012
- Pfizer Files Lawsuit Against Sandoz for Generic Lipitor, Sandoz to Contest Action
March 2, 2012
- Carna Biosciences Aiming to Out-License First Products to Megapharma in 2012 “if Possible”
March 2, 2012
- Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
- SBI to Enter Pharmaceutical Business Through Subsidiary, Considering Domestic Plant
March 1, 2012
- Takeda Initiates PIII Clinical Trials of Leuplin 6-Month Depot Formulation in Japan
March 1, 2012
- Takeda to Issue Straight Bonds for the First Time in 25 Years to Cover Nycomed Acquisition
March 1, 2012
- Takeda to Operate Global Vaccine Business, Aiming to Join Top 5 in 10 Years
March 1, 2012
- DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…